Legiran
Department of Anatomy, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search
Journal : Bioscientia Medicina : Journal of Biomedicine and Translational Research

Epidemiology and Risk Factors for Cervical Cancer Patiyus Agustiansyah; Rizal Sanif; Siti Nurmaini; Irfannuddin; Legiran
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 7 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i7.326

Abstract

Cervical cancer in Indonesia in 2018 ranks second in cancer in women in Indonesia with an incidence rate of 348.809 cases with a mortality rate of nearly 60% of the incidence, namely 207.210 deaths. Deaths from cervical cancer are projected to continue to increase and are estimated to reach 12 million deaths by 2030 if not treated properly. The incidence of cervical cancer in Indonesia is estimated to have 180.000 new cases per year and the death rate is thought to reach 75% in the first year. This death is mainly associated with the majority of newly diagnosed patients who are already at an advanced stage (70% of cases) and are already at the terminal stage at the time of diagnosis.
Human Papilloma Virus: Biomolecular Aspect Patiyus Agustiansyah; Rizal Sanif; Siti Nurmaini; Irfannuddin; Legiran
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 8 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i8.327

Abstract

HPV is a sexually transmitted virus, and high-risk HPV DNA was found in 99.7%of cervical cancer specimens. Within 12 to 24 months of exposure to the virus,90% of HPV infections disappear or become inactive. However, infection with high-risk strains of HPV persist which then increases the risk of progression to cervicalcancer. The detection of precancerous lesions consists of various methods,including pap smear (conventional or liquid-base cytology / LBC), visualinspection of acetic acid (IVA), visual inspection of lugoliodine (VILI), and HPV DNAtest (genotyping / hybrid capture).
WHO Global Strategy in Eradication of Cervical Cancer Patiyus Agustiansyah; Rizal Sanif; Siti Nurmaini; Irfannuddin; Legiran
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 9 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i9.328

Abstract

WHO has created a global strategy to accelerate the elimination of cervical canceras a public health problem and a world burden. Cervical cancer is a disease thatcan be prevented and cured, as long as it is detected early and treated effectively.Cervical cancer is also a disease that reflects global injustice. The burden isgreatest in low- and middle-income countries, where access to public healthservices is limited and screening and treatment for the disease has not been widelyapplied. In 2018, nearly 90% of all deaths worldwide occurred in low and middleincome countries. Furthermore, the proportion of women with cervical cancer whodie from the disease is more than 60% in these countries, more than double thenumber in many high-income countries, which is only 30%.
Screening for Cervical Cancer Patiyus Agustiansyah; Rizal Sanif; Siti Nurmaini; Irfannuddin; Legiran
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 10 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i10.329

Abstract

Screening is a public health intervention administered to a target population without symptoms. Screening is not performed to diagnose a disease, but to identify individuals with a higher likelihood of developing the disease itself or a precursor to the disease. Not all diseases are suitable for screening programs. The following criteria help determine whether a disease is suitable for a screening program: (1) The disease is bound to have serious consequences. (2) The disease must have a detectable preclinical and asymptomatic stage. (3) Treatment at the preclinical stage should influence the long-term course and prognosis of the disease being screened. (4) Care must be available and accessible to those who have a positive screening test. History, screening tests and treatment options for cervical pre-cancer meet these criteria.